

1 **INTERIM REPORT: SAFETY AND IMMUNOGENICITY OF AN INACTIVATED VACCINE**
2 **AGAINST SARS-COV-2 IN HEALTHY CHILEAN ADULTS IN A PHASE 3 CLINICAL TRIAL**

3

4 **Brief Title:** CoronaVac03CL Phase 3 Interim Analysis of Safety and Immunogenicity.

5

6 Susan M Bueno^{1,2*}, Katia Abarca^{1,3}, Pablo A González^{1,2}, Nicolás MS Gálvez^{1,2}, Jorge A Soto^{1,2},
7 Luisa F Duarte^{1,2}, Bárbara M Schultz^{1,2}, Gaspar A Pacheco^{1,2}, Liliana A González^{1,2}, Yaneisi
8 Vázquez^{1,2}, Mariana Ríos^{1,2}, Felipe Melo-González^{1,2}, Daniela Rivera-Pérez^{1,2}, Carolina
9 Iturriaga³, Marcela Urzúa³, Angélica Dominguez⁴, Catalina A Andrade^{1,2}, Roslye V Berrios^{1,2},
10 Gisela Canedo-Marroquín^{1,2}, Camila Covián^{1,2}, Daniela Moreno-Tapia^{1,2}, Farides Saavedra^{1,2},
11 Omar P Vallejos^{1,2}, Paulina Donato⁵, Pilar Espinoza^{6,7}, Daniela Fuentes⁸, Marcela González^{9,10},
12 Paula Guzmán¹¹, Paula Muñoz-Venturelli¹², Carlos M Pérez^{6,7}, Marcela Potin¹³, Alvaro Rojas¹⁴,
13 Rodrigo Fasce¹⁵, Jorge Fernández¹⁵, Judith Mora¹⁵, Eugenio Ramírez¹⁵, Aracelly Gaete-Argel¹⁶,
14 Aarón Oyarzún-Arrau¹⁶, Fernando Valiente-Echeverría¹⁶, Ricardo Soto-Rifo¹⁶, Daniela
15 Weiskopf¹⁷, Alessandro Sette¹⁷, Gang Zeng¹⁸, Weining Meng¹⁸, José V González-Aramundiz¹⁹,
16 Alexis M Kalergis^{1,2,20*}

17

18 ¹Millennium Institute on Immunology and Immunotherapy.

19 ²Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas,
20 Pontificia Universidad Católica de Chile, Santiago, Chile.

21 ³Departamento de Enfermedades Infecciosas e Inmunología Pediátrica, División de Pediatría,
22 Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.

23 ⁴Departamento de Salud Pública, Facultad de Medicina, Pontificia Universidad Católica de
24 Chile.

25 ⁵Complejo Asistencial Dr. Sótero del Río, Santiago, Chile.

26 ⁶Hospital Clínico Félix Bulnes.

27 ⁷Facultad de Medicina y Ciencia, Universidad San Sebastián, Santiago, Chile.

28 ⁸Hospital Carlos Van Buren, V Región, Chile.

29 ⁹Hospital Dr. Gustavo Fricke, V Región, Chile.

30 ¹⁰Departamento de Pediatría, Universidad de Valparaíso.

31 ¹¹Clínica Los Andes, Universidad de Los Andes, Santiago, Chile.

32 ¹²Facultad de Medicina, Clínica Alemana Universidad del Desarrollo, Santiago, Chile.

33 ¹³Clínica San Carlos de Apoquindo, Red de Salud UC Christus, Santiago, Chile.

34 ¹⁴Departamento de Enfermedades Infecciosas del Adulto, División de Medicina, Escuela de
35 Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.

36 ¹⁵Departamento de Laboratorio Biomédico, Instituto de Salud Pública de Chile.

37 ¹⁶Laboratory of Molecular and Cellular Virology, Virology Program, Institute of Biomedical
38 Sciences, Faculty of Medicine, Universidad de Chile, Santiago, Chile.

39 ¹⁷Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La
40 Jolla, CA 92037, USA.

41 ¹⁸Sinovac Biotech, Beijing, China.

42 ¹⁹Departamento de Farmacia, Facultad de Química y de Farmacia. Pontificia Universidad
43 Católica de Chile, Santiago, Chile.

44 ²⁰Departamento de Endocrinología, Facultad de Medicina, Escuela de Medicina, Pontificia
45 Universidad Católica de Chile, Santiago, Chile.

46

47 *Corresponding author: Alexis M Kalergis and Susan M Bueno, Pontificia Universidad Católica
48 de Chile. Av. Libertador Bernardo O'Higgins N° 340, Santiago 8331010, Santiago, Chile. Phone
49 56-2-6862846, e-mail addresses: akalergis@bio.puc.cl, sbueno@bio.puc.cl.

50 Keywords: SARS-CoV-2, CoronaVac®, phase 3 clinical trial, safety, immunogenicity, Chile.

51 **Abstract**

52 **Background:** The ongoing COVID-19 pandemic has had a significant impact worldwide, with
53 an incommensurable social and economic burden. The rapid development of safe and
54 protective vaccines against this disease is a global priority. CoronaVac is a vaccine prototype
55 based on inactivated SARS-CoV-2, which has shown promising safety and immunogenicity
56 profiles in pre-clinical studies and phase 1/2 trials in China. To this day, four phase 3 clinical
57 trials are ongoing with CoronaVac in Brazil, Indonesia, Turkey, and Chile. This article reports
58 the safety and immunogenicity results obtained in a subgroup of participants aged 18 years and
59 older enrolled in the phase 3 Clinical Trial held in Chile.

60 **Methods:** This is a multicenter phase 3 clinical trial. Healthcare workers aged 18 years and
61 older were randomly assigned to receive two doses of CoronaVac or placebo separated by two
62 weeks (0-14). We report preliminary safety results obtained for a subset of 434 participants, and
63 antibody and cell-mediated immunity results obtained in a subset of participants assigned to the
64 immunogenicity arm. The primary and secondary aims of the study include the evaluation of
65 safety parameters and immunogenicity against SARS-CoV-2 after immunization, respectively.
66 This trial is registered at clinicaltrials.gov (NCT04651790).

67 **Findings:** The recruitment of participants occurred between November 27th, 2020, until January
68 9th, 2021. 434 participants were enrolled, 397 were 18-59 years old, and 37 were ≥ 60 years old.
69 Of these, 270 were immunized with CoronaVac, and the remaining 164 participants were
70 inoculated with the corresponding placebo. The primary adverse reaction was pain at the
71 injection site, with a higher incidence in the vaccine arm (55.6%) than in the placebo arm
72 (40.0%). Moreover, the incidence of pain at the injection site in the 18-59 years old group was
73 58.4% as compared to 32.0% in the ≥ 60 years old group. The seroconversion rate for specific
74 anti-S1-RBD IgG was 47.8% for the 18-59 years old group 14 days post immunization (p.i.) and
75 95.6% 28 and 42 days p.i. For the ≥ 60 years old group, the seroconversion rate was 18.1%,
76 100%, and 87.5% at 14, 28, and 42 days p.i., respectively. Importantly, we observed a 95.7%
77 seroconversion rate in neutralizing antibodies for the 18-59 years old group 28 and 42 days p.i.

78 The ≥ 60 years old group exhibited seroconversion rates of 90.0% and 100% at 28 and 42 days
79 p.i. Interestingly, we did not observe a significant seroconversion rate of anti-N-SARS-CoV-2
80 IgG for the 18-59 years old group. For the participants ≥ 60 years old, a modest rate of
81 seroconversion at 42 days p.i. was observed (37.5%). We observed a significant induction of a
82 T cell response characterized by the secretion of IFN- γ upon stimulation with Mega Pools of
83 peptides derived from SARS-CoV-2 proteins. No significant differences between the two age
84 groups were observed for cell-mediated immunity.

85 **Interpretation:** Immunization with CoronaVac in a 0-14 schedule in adults of 18 years and older
86 in the Chilean population is safe and induces specific IgG production against the S1-RBD with
87 neutralizing capacity, as well as the activation of T cells secreting IFN- γ , upon recognition of
88 SARS-CoV-2 antigens.

89 **Funding:** Ministry of Health of the Chilean Government; Confederation of Production and
90 Commerce, Chile; Consortium of Universities for Vaccines and Therapies against COVID-19,
91 Chile; Millennium Institute on Immunology and Immunotherapy.

92 Introduction

93 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the emerging
94 pathogen responsible for coronavirus disease 2019 (COVID-19) ¹⁻³. This virus was first
95 described in December 2019 in Wuhan, China, and it is the source of the ongoing pandemic,
96 which has resulted by March 2021 in almost 130 million cases and over 2,7 million deaths
97 worldwide ⁴. Due to its novelty and impact on human health, international efforts are focused on
98 generating vaccines to counteract COVID-19. Epidemiological studies show that individuals
99 aged ≥ 60 and those with chronic conditions are more susceptible to severe disease, frequently
100 resulting in death ^{5,6}. To date, more than 180 vaccines are under development, with over 80 of
101 them in clinical trials, 18 undergoing phase 3 or phase 4 clinical trials, and 10 approved for
102 emergency use ⁷. While many different vaccine platforms are being used and explored, most of
103 them rely on a single viral component, namely the full-length Spike (S) protein or the receptor-
104 binding domain (RBD) of Spike^{7,8}.

105 CoronaVac is an inactivated SARS-CoV-2 vaccine, developed by Sinovac Life Sciences
106 Co., Ltd. (Beijing, China) ⁹. Sinovac received approval from the NMPA in China in April 2020 to
107 conduct phase 1/2 studies of this vaccine candidate in that country after demonstrating that it
108 was safe and immunogenic in different animal models, such as rodents and non-human
109 primates ⁹. Phase 1/2 clinical trials in China were carried out as randomized, double-blind, and
110 placebo-controlled studies. In these trials, two vaccination schedules were evaluated: two doses
111 separated by 14 days (0-14) or 28 days (0-28) ^{10,11}. Overall, these studies reported one severe
112 adverse event (SAE) possibly related to the vaccine during the phase 2 trial with participants
113 aged 18-59, which resolved within three days ¹⁰. There were eight SAEs in the ≥ 60 years old
114 age group, but all were unrelated to the vaccine ¹¹. Both phase 2 trials showed that this vaccine
115 induces neutralizing antibodies 14 days after the second dose ^{10,11}. The neutralizing antibody
116 seroconversion rate was above 92% in participants aged 18-59, and above 94% for participants
117 aged ≥ 60 , using two 3 μg doses in the 0-28 schedule ^{10,11}. The results from these clinical trials

118 suggest that this vaccine is safe and likely induces a protective immune response against
119 SARS-CoV-2.

120 Currently, four phase 3 clinical trials are evaluating the efficacy of CoronaVac, and are
121 being carried out in Brazil, Turkey, Indonesia, and Chile. Here, we report an interim analysis of
122 safety and immunogenicity parameters upon immunization of the Chilean population with
123 CoronaVac or placebo in healthcare workers aged 18-59 and ≥ 60 in a 0-14 days vaccination
124 schedule. A total of 434 participants were evaluated, 397 aged 18-59 and 37 aged ≥ 60 . Given
125 that this vaccine carries multiple SARS-CoV-2 antigens, the characterization of the humoral and
126 cellular immune response was extended to other components of the viral proteome beyond
127 Spike. Taken together, this is the first report characterizing the cellular and humoral immune
128 responses elicited by CoronaVac in a population other than the Chinese. Our results indicate
129 that CoronaVac is safe and immunogenic in adults aged 18-59 and ≥ 60 in the Chilean
130 population.

131 **Materials and Methods**

132 **Study design, randomization, and participants**

133 This clinical trial (clinicaltrials.gov NCT04651790) was conducted in Chile at eight
134 different sites. The study protocol was conducted according to the current Tripartite Guidelines
135 for Good Clinical Practices, the Declaration of Helsinki ¹², and local regulations. The trial
136 protocol was reviewed and approved by the Institutional Scientific Ethical Committee of Health
137 Sciences, Pontificia Universidad Católica de Chile, Approval #200708006 (Committee
138 members: Claudia Uribe PUC/Committee president; Colomba Cofré/Committee Vice-president;
139 Andréa Villagrán/Executive secretary; Jorge Muñoz/External Lawyer; Gustavo
140 Kaltwasser/External member; Alysa Garay/Community representative; Marisa Torres/Public
141 Health Department; Carolina Méndez/Speech therapy representative; Luis Villarroel/Public
142 Health Department; Pablo Brockman/Respiratory Diseases in Children Department. Website:
143 <http://eticayseguridad.uc.cl/comite-etico-cientifico-facultad-de-medicina-uc.html>). Trial execution
144 was approved by the Chilean Public Health Institute (#24204/20). Written informed consent was
145 obtained from each participant before enrollment. The study included healthcare workers who
146 were in contact with possible or confirmed cases of COVID-19 ≥ 18 years old. Participants were
147 inoculated with either two doses of 3 μg (600SU) of CoronaVac or placebo at 0- and 14-days
148 post the first immunization (p.i.). Exclusion criteria included, among others, history of confirmed
149 symptomatic SARS-CoV-2 infection, pregnancy, allergy to vaccine components, and
150 immunocompromised conditions. Well-controlled medical conditions were allowed. A complete
151 list of inclusion/exclusion criteria is provided in the study protocol.

152 Participants were randomly assigned to immunization with CoronaVac or injection with
153 placebo in a 1:1 ratio. A subgroup of participants was assigned to the immunogenicity arm, and
154 they received randomly either CoronaVac or placebo (3:1 ratio). The randomization process
155 was done using a sealed enveloped system integrated into the electronic Case Report Forms
156 (eCRF) in the OpenClinica platform. All participants, blind investigators, and laboratory staff
157 were masked to arm allocation. A total of 434 participants were enrolled up to January 9th, 2021.

158 The immunogenicity arm includes 190 participants. Table 1 summarizes the characteristics of
159 the participants, and Figure 1 shows the study profile.

160

161 **Procedures**

162 CoronaVac consists of 3 μ g of β -propiolactone inactivated SARS-CoV-2 (strain CZ02)
163 with aluminum hydroxide as an adjuvant in 0.5 mL⁹. More details on excipients and the Placebo
164 can be found in the Supplementary Material. A non-blind study nurse was in charge of
165 administering intramuscularly in the deltoid area the contents of ready-to-use syringes loaded
166 with either CoronaVac or placebo to participants. For the immunogenicity arm, blood samples
167 were obtained at different time points and were used for the isolation of sera and PBMC. For
168 sera samples, 20 mL of blood were collected. For PBMC isolation, 30 mL of blood were
169 collected in heparinized tubes. Details regarding isolation of sera and PBMCs can be found in
170 the Supplementary Material.

171 To assess the presence of anti-SARS-CoV-2 antibodies, blood samples from 39
172 participants obtained at days 0 (baseline), 14, 28, and 42 p.i. were analyzed. The quantitative
173 measurement of human IgG antibodies against the RBD domain of the S1 protein (S1-RBD)
174 and against the N protein of SARS-CoV-2 was determined using the RayBio COVID-19 (SARS-
175 CoV-2) Human Antibody Detection Kit (Indirect ELISA method) (Cat #IEQ-CoVS1RBD-IgG &
176 #IEQ-CovN-IgG). Details on the characteristics and the methodology of these kits can be found
177 on the Supplementary Material. The neutralizing capacities of the antibodies in the samples of
178 the participants were evaluated through the SARS-CoV-2 surrogate virus neutralization test
179 (sVNT) kit from Genscript (cat. number L00847-A). Assays were performed according to the
180 instructions of the manufacturer and further details can be found on the Supplementary Material.

181 To assess the cellular immune response, ELISPOT and flow cytometry assays were
182 performed using PBMCs from 36 participants. Stimulus included in these assays considers the
183 use of Mega Pools (MPs) of peptides derived from SARS-CoV-2 proteins, previously described
184 ¹³. Two MPs composed of peptides from the S protein (MP-S) and the remaining proteins of the

185 viral particle (MP-R) were used. Also, two MPs composed of peptides from the whole proteome
186 of SARS-CoV-2 (CD8-A and CD8-B) were used. Corresponding positives and negative controls
187 were held. A total of 3×10^5 cells in 50 μ L of media were added to each well containing 50 μ L of
188 media with the corresponding stimulus. For ELISPOT assays, cells were incubated for 48h at
189 37°C, 5% CO₂. Further details regarding the ELISPOT protocol can be found in the
190 Supplementary Materials. To characterize T cells and the production of cytokines by these
191 populations, flow cytometry assays were performed. A total of 3×10^5 cells per well were
192 stimulated with the same stimulus indicated above. 24h after incubation, samples were stained
193 to evaluate the expression of surface and intracellular markers. Further details on the antibodies
194 used and the protocol can be found in the Supplementary Materials.

195

196 **Outcomes**

197 The primary aim was to evaluate the frequency of solicited and unsolicited AEs that
198 occur during 7 days after each dose, stratified by age group (aged 18-59 and ≥ 60). Grading for
199 solicited and unsolicited AEs can be found in detail in the Table S1, S2, and S3 of the
200 Supplementary Materials. Secondary safety endpoints include the frequency of any other AE
201 occurring 28 days after each dose, SAEs, and Events of Special Interest in any moment, and
202 their relationship with the investigational vaccine. Secondary immunogenic endpoints
203 considered, among others, the assessment of the presence of anti-SARS-CoV-2 antibodies and
204 the cellular immune response elicited by the vaccine in a subgroup of participants, at days 0, 28,
205 and 42 p.i.. A complete list of outcomes can be found in the study protocol.

206

207 **Statistical analysis**

208 To determine the sample size to use in this trial, the parameters used were a protection
209 rate of the vaccine of ($\mu = 0.5$); an incidence rate in the population group of 6%; $\alpha = 0.05$; $1 - \beta =$
210 0.9. A total of 1,068 participants need to be recruited in each group. Considering a 10% rate of
211 withdrawal, the sample size in each group was defined as 1,175.

212 Safety analysis considers all AEs (solicited and unsolicited) that occurred after each
213 injection. All AEs were coded and grouped according to MedDRA (Medical Dictionary for
214 Regulatory Activities) methodology. Solicited AEs (local and systemic) are presented in a
215 summarized form according to frequency, their maximum intensity, and duration per participant.
216 Rates were compared between several groups (vaccine v/s placebo; 18-59 v/s ≥ 60 years old;
217 first v/s second dose) using a two-tailed Pearson's Chi-square or Fisher's exact test. Unsolicited
218 AEs with a frequency of 1% or more; SAEs; and Events of Special Interest are presented.

219 To evaluate statistical differences in the immunogenicity data, one- or two-way non-
220 parametric ANOVAs (Friedman test) with the corresponding *post hoc* test (Dunn's test corrected
221 for multiple comparisons) or Wilcoxon tests or two-tailed Student's t-test (for comparisons
222 between two groups) were performed depending on the assay. The significance level was set at
223 0.05. All data were analyzed with GraphPad Prism 9.0.1. or SPSS 17.0.

224 **Role of the funding source**

225 The funding sources of this study had no role in study design, data collection, analysis,
226 and interpretation, or writing of the article. All the listed authors had full access to all the data in
227 the study and agreed to submit it for publication.

228 Results

229 1. CoronaVac shows a favorable safety profile in adults aged 18-59 and ≥ 60 in the Chilean 230 population.

231 Participants of this phase of the study were recruited between November 27th, 2020, and
232 January 9th, 2021. 434 participants were enrolled, with 397 aged 18-59 and 37 aged 60-75. 268
233 participants were women (61.7%), and 166 were men (38.3%). The mean age (SD) was 39.7 (\pm
234 11.8) years in the placebo arm and 40.9 (\pm 11.9) in the vaccine arm. 319 participants received
235 two doses of either CoronaVac or placebo (286 in the 18-59 age group and 33 in the ≥ 60 age
236 group). The vaccination schedule for both groups was 0-14. The demographic characteristics of
237 the participants are summarized in Table 1.

238 A list of local and systemic solicited AEs observed after each vaccine dose is shown in
239 Table 2. The most-reported solicited local AEs was pain at the injection site, with an incidence
240 of 55.6% in the vaccine arm as compared to 40.0% in the placebo arm (p-value = 0.015).
241 Symptoms usually started after vaccination and were resolved within two days, with
242 predominantly mild (grade 1) severity (98%, 91%, and 100%, respectively). Local AEs were
243 more frequent in the vaccine arm (278 events) than in the placebo arm (78 events). Headaches
244 were the most common solicited systemic AEs with a frequency of 48.5% in the vaccine arm
245 and 48.8% in the placebo arm. Intensity of AEs was mostly mild or moderate. No serious
246 adverse events (SAEs) nor Events of Special Interest were reported in either arm. Significant
247 differences were observed between age groups regarding the frequency of local and systemic
248 AEs (Table S4): pain was present in 47.1% of the 18-59 years old group in contrast to 29.7% in
249 the ≥ 60 years old group (p-value = 0.009), while headache was present in 42.4% and 27.0%,
250 respectively (p-value = 0.026). This association remained present in the vaccine arm but not in
251 the placebo arm.

252 A total of 55 unsolicited AEs were reported. Those with a frequency of 1% or more were
253 gastrointestinal discomfort (n=7), abdominal pain (n=5), odynophagia (n=5), and back pain
254 (n=4). During the study period, three COVID-19 cases occurred (breakthrough cases). Two

255 were detected at enrolment: one of them developed anosmia in the following days, and another
256 after the first dose. One of them had a clinical progression score of 1 (asymptomatic), and the
257 other two had a score of 2 (symptomatic, independent)¹⁴. No SAEs nor other events of special
258 interest occurred in this study period.

259

260 **2. Immunization with CoronaVac in a 0-14 schedule induces the secretion of IgG against**
261 **the S1-RBD of SARS-CoV-2 with potentially neutralizing capacities in adults aged 18-59**
262 **and ≥60.**

263 Evaluation of IgG specific against S1-RBD and the N protein of SARS-CoV-2 was
264 performed independently using ELISA assays (Fig. S1 and S2). A total of 32 participants aged
265 18-59 (23 in the vaccine arm and 9 in the placebo arm) and 14 participants aged ≥60 were
266 evaluated (11 in the vaccine arm and 3 in the placebo arm). Four of the participants aged 18-59
267 were identified as seropositive at the time of recruitment. Seroconversion rates for the S1-RBD
268 specific IgG (Table 3 - Upper) were 47.8% 14 days p.i. in participants aged 18-59 (GMT 23.1)
269 and 18.1% at the same time point in participants aged ≥60 (GMT 45.1). At 28 and 42 days p.i.,
270 seroconversion rates reached 95.6% in participants aged 18-59 (GMT 1,755 and 1,878 at day
271 28 and 42 p.i., respectively). Seroconversion rates in participants aged ≥60 reached 100% at
272 day 28 p.i. (GMT 1,860.2) and 87.5% at day 42 p.i. (GMT 1,878) (Table 3 and Figure 2).
273 Interestingly, the seroconversion rates for IgG specific against the N protein (Table 3 – Middle)
274 14 days p.i. was 8.7% for participants aged 18-59 (GMT 5.3) and 0% for participants aged ≥60
275 (GMT 5.5). On day 28 p.i., the seroconversion rates were 17.4% for the 18-59 years old group
276 and 20.0% ≥60 years old group (GMT 8.0 and 9.6 respectively), which increased up to 37.5%
277 for the participants ≥60 years old (GMT 32.6) and decreased to 13.0% in participants aged 18-
278 59 (GMT 9.2) 42 days p.i. (Table 3 and Figure 2). The results obtained for the seropositive
279 participants at enrollment and breakthrough cases are shown in Table S5. These results
280 suggest that CoronaVac induces a significant production of S1-RBD specific IgG after
281 immunization with a 0-14 scheme but induces a weak production of IgG specific against the N

282 protein. We confirmed that doses of CoronaVac contain significant amounts of the N protein
283 (Fig. S3).

284 To evaluate the potential neutralizing capacities of these antibodies, a sVNT was
285 performed. This test detects whether antibodies present in the sera interfere with the binding of
286 S1-RBD to the hACE2 receptor. Serum samples used were obtained from 44 participants aged
287 18-59 (23 in the vaccine arm and 8 in the placebo arm) and 14 participants aged ≥ 60 (10 in the
288 vaccine arm and 3 in the placebo arm), at 0, 28, and 42 days p.i.. An inhibition rate of $\leq 30\%$ was
289 set as the negative cut-off for this assay. We observed that the titers of antibodies against the
290 RBD region increased significantly 28 and 42 days p.i. as compared to day 0. The GMTs
291 calculated for the antibody titers in participants aged 18-59 were 15.1 on day 28 p.i., and 17.5
292 on day 42 p.i., (Fig. 3A). Regarding the ≥ 60 years old group, the GMTs were 39.4 and 48.5, at
293 28 and 42 days p.i., respectively (Fig. 3B). The seroconversion rate was 96% for the 18-59 age
294 group at 28 and 42 days p.i. and 90% and 100% for the ≥ 60 age group at these times. The
295 neutralizing capacities of antibodies induced by vaccination were also evaluated by three
296 additional methodologies (pseudotyped virus assay¹⁵, BioHermes surrogate VNT and
297 neutralization of live SARS-CoV-2), showing similar results (Fig. S4). These results suggest that
298 immunization with CoronaVac in a 0-14 schedule promotes the production of anti-S1-RBD IgG
299 with neutralizing capacities in both age groups.

300

301 **3. Immunization with CoronaVac in a 0-14 schedule induces IFN- γ -producing T cells** 302 **specific for SARS-CoV-2 antigens in adults aged 18-59 and ≥ 60 in the Chilean population.**

303 To evaluate the cellular immune response elicited upon vaccination with CoronaVac, the
304 specific T cell responses against MP of peptides derived from the S protein of SARS-CoV-2
305 (MP-S) and the remaining proteins of this virus (MP-R) were evaluated by ELISPOT and flow
306 cytometry assays in a total of 36 participants from the vaccine arm (27 aged 18-59 and 9 aged
307 ≥ 60) and 6 from the placebo arm. We observed an increase in the number of Spot Forming
308 Cells (SFCs) for IFN- γ at 28 and 42 days p.i. as compared to day 0, upon stimulation with both

309 the MP-S and the MP-R (Fig. 4A and B). This tendency was seen for participants aged 18-59
310 and ≥ 60 (Fig. 4). Similar trends were observed when a fold change analysis of this increase was
311 performed and normalized to day 0 (Fig. S5). In the 18-59 age group, the number of SFCs for
312 IFN- γ producing T cells showed an average increase of 14.04 and 9.76 times for the MP-S and
313 31.78 and 18.67 times for the MP-R at 28 and 42 days p.i., respectively. In the ≥ 60 years old
314 group, an average increase of 20.04 and 9.63 times was observed for the MP-S, and 33.81 and
315 20.28 times for the MP-R at 28 and 42 days p.i., respectively. Participants in the placebo arm
316 exhibited no differences in the number of SFCs for IFN- γ among the different stimuli and time
317 points evaluated (Fig. S6). The response detected in the ELISPOT assays suggests that
318 immunization with CoronaVac induces a T cell response polarized towards a Th1 immune
319 profile, as the secretion of IL-4 by T cells was mainly undetected (Fig. S7). As a positive control,
320 PBMCs from participants were stimulated with an MP of peptides derived from cytomegalovirus
321 (CMV) (Fig. S8).

322 Since MP-S and MP-R were originally determined *in silico* to optimally stimulate CD4⁺ T
323 cells, the activation and the secretion of Th1 cytokines by these cells upon stimulation were
324 evaluated by flow cytometry. Remarkably, the absolute numbers of activated CD4⁺ T cells
325 (defined as CD3⁺, CD4⁺, CD69⁺) increased at 28 days p.i. as compared to day 0 in both age
326 groups (Fig. S9A and Table S6). The absolute number of the activated CD4⁺ T cells secreting
327 IFN- γ showed an evident increase at 28 days p.i. in the 18-59 years old group, upon stimulation
328 with both MP-S and MP-R (Fig. 4C and D). However, this trend was not evident for the ≥ 60
329 years old group, primarily upon stimulation with the MP-S. A fold change analysis of the
330 activated CD4⁺ T cells secreting IFN- γ at days 28 and 42 p.i., compared to day 0, also suggests
331 that an increase is observed for the 18-59 years old group, but not for the ≥ 60 years old group
332 (Table S6). We also evaluated the absolute numbers (Fig. S10) and the fold change (Table S6)
333 of activated CD4⁺ T cells producing IL-2 or TNF- α upon stimulation with MP-S and MP-R,
334 evidencing variable trends among both age groups, 28 and 42 days p.i., compared to day 0.

335 The specific T cell responses against MP of peptides chosen from the whole proteome
336 of SARS-CoV-2 (MP-CD8A and MP-CD8B) was also evaluated in 7 participants aged 18-59 and
337 7 participants aged ≥ 60 . In most of the participants evaluated for the 18-59 age group,
338 stimulation with MP-CD8A and CD8B resulted in a modest increase in SFCs for IFN- γ 28 and 42
339 days p.i. compared to day 0 (Fig. 5A and B). However, a partial rise in SFCs producing IFN- γ
340 was observed upon stimulation with both MP-CD8A and MP-CD8B for some participants aged
341 ≥ 60 (Fig. 5B), at 28 and 42 days p.i.. There was a subtle fold increase in the number of SFCs
342 positive for IFN- γ in participants aged 18-59 and a more evident fold increase in participants
343 aged ≥ 60 with both MP, at 28 and 42 days p.i. (Fig. S11). No marked differences were detected
344 for the placebo arm participants among the different stimuli and times evaluated (Fig. S12).

345 Since the peptides included in MP-CD8A and MP-CD8B were determined *in silico* to
346 stimulate CD8⁺ T cells, the activation and the secretion of Th1 cytokines by these cells upon
347 stimulation was measured by flow cytometry, as described in ¹³. Variable changes were seen in
348 the activation of CD8⁺ T cells (defined as CD3⁺, CD8⁺, CD69⁺), and the secretion of cytokines
349 by these cells. For both groups, the absolute number of activated CD8⁺ T cells showed no
350 significant variation at 28 and 42 days p.i. compared to day 0 (Fig. S13). Minor increases at 28
351 days p.i. were observed for the absolute numbers of CD8⁺ T cells that produced the cytokines
352 IFN- γ in both age groups (Fig. 5C and D). Fold change analysis of these results can be found on
353 Table S6. We also evaluated absolute numbers (Fig. S14) and fold increases (Table S6) of
354 activated CD8⁺ T cells producing IL-2 or TNF- α upon stimulation with MP-CD8A and MP-CD8B.
355 Variable trends for these cells at 28 and 42 days p.i. for both groups were detected, as
356 compared to day 0. Although a higher number of participants must be evaluated, ELISPOT and
357 flow cytometry results suggest that stimulation with MP-CD8A and MP-CD8B can, to some
358 extent, induce a cellular immune response in participants immunized with CoronaVac.

359 Overall, these results suggest that CoronaVac can induce a humoral immune response
360 based on total and neutralizing antibodies and a CD4⁺ T cell response polarized towards a Th1
361 profile in adults aged 18 and older, which targets several SARS-CoV-2 antigens.

362 Discussion

363 This study is a first preliminary analysis of a phase 3 clinical trial performed in Chile with
364 CoronaVac, an inactivated vaccine against SARS-CoV-2. Results show that this vaccine has a
365 favorable safety and immunogenicity profile in the Chilean population. Although further analyses
366 including more participants are needed, the results shown here are similar to those obtained in
367 previous clinical trials with CoronaVac^{10,11}. We found that two doses of CoronaVac, in a 0-14
368 schedule, were safe and capable of inducing a humoral and cellular immune response in both
369 age groups evaluated (18-59 and ≥ 60 years old). A different immunization schedule considering
370 a booster at day 28 p.i. instead of day 14 p.i. is being currently tested, in line with results
371 recently reported on the Chinese population¹⁰. Further studies will focus on this new
372 immunization schedule.

373 Adverse reactions observed were primarily mild and local, which coincides with previous
374 reports with this vaccine. The most reported solicited local AE was pain at the injection site in
375 the vaccine arm resolved within two days after vaccination. Headache was the most systemic
376 common solicited AE registered in the vaccine and the placebo arm, at a similar frequency. No
377 SAEs were reported for either the vaccine or placebo arm. Interestingly, we detected differences
378 between the age groups regarding the frequency of local and systemic AEs. These were more
379 frequent in the 18-59 years old group than in the ≥ 60 years old group.

380 The antibody response elicited by the Chilean population was similar to the one reported
381 previously. We detected over 90% seroconversion for S1-RBD-specific IgG, along with over
382 90% of seroconversion for neutralizing antibodies at 28 and 42 days p.i.. These rates are
383 consistent with the data reported in the phase 2 trial conducted in China (100% for RBD-specific
384 IgG and 99.2% for neutralizing antibodies) for the same immunization scheme, dose, and age
385 ¹⁰. Although seroconversion rates are slightly lower in participants aged ≥ 60 at 42 days p.i.,
386 these results are promising, as the vaccine may exhibit a protective profile in older populations.
387 Differences in the seroconversion rates and antibodies neutralizing capacities seen among the

388 different methodologies tested may be directly related with the intrinsic characteristics of each
389 methodology (i.e. sVNA, pseudotype virus neutralization assays, and infection inhibition).

390 We observed a low secretion of anti-N antibodies as compared to IgG induced against
391 the S1-RBD, which is not related to the absence of the N protein in CoronaVac. Previous
392 reports indicate that humans naturally infected with SARS-CoV-2 develop antibody responses
393 mainly to the S and N proteins, in somewhat similar levels⁹. However, immunization studies of
394 mice, rats, and non-human primates with CoronaVac showed that the antibodies induced were
395 mostly directed against the S protein and the S1-RBD, with a reduced amount of antibodies
396 against the N protein⁹. This is in line with our findings, suggesting that the enhanced secretion
397 of antibodies against the S protein by CoronaVac, rather than against the N protein, may be
398 playing a role in the protective response induced by the vaccine. This may also have significant
399 considerations when choosing techniques for the confirmation of infections with SARS-CoV-2,
400 as anti-N antibodies may not be mostly detected in immunized individuals.

401 This is the first time a characterization of the cellular response against proteins other
402 than the S protein of SARS-CoV-2 is reported in humans immunized with CoronaVac. Unlike
403 previous studies¹⁰, we detected a robust T cell response upon stimulation of PBMCs with MPs
404 of peptides from S (MP-S) and the remaining viral particle (MP-R). There was a clear increase
405 in the number of SFCs for IFN- γ when PBMC from days 28 and 42 p.i. were stimulated with MP-
406 S and MP-R, which was also evident in the fold changes calculated compared to day 0. An
407 increase in the number of activated CD4⁺ T cells secreting IFN- γ upon stimulation with these
408 stimuli in those time points was detected. However, a reduced number was observed in the ≥ 60
409 years old group stimulated with MP-S. This observation could be explained by a natural
410 reduction of activated CD4⁺ T cells in the older population, previously described for other
411 vaccines¹⁶. We also evaluated the response elicited upon stimulation with two MPs of peptides
412 designed to stimulate a CD8⁺ T cell response (MP-CD8A and MP-CD8B). Stimulation with MP-
413 CD8 (A and B) resulted in increased SFCs for IFN- γ in some participants in the 18-59 years old
414 group and the ≥ 60 years old group. We did not observe an evident increase in the number of

415 activated CD8⁺ T cells secreting IFN- γ at days 28 and 42 p.i. in none of the age groups.
416 Although more participants will be evaluated to raise more robust conclusions, the results
417 obtained so far suggest that the CD8⁺ immune response detected in vaccinated participants is
418 not as robust as the CD4⁺ immune response. Since the secretion of IFN- γ by CD4⁺ T cells and
419 reduced amounts of IL-4 secreting cells are in line with a well-balanced immune response that
420 could achieve virus clearance, immunization with CoronaVac shows promising capacities of
421 inducing an antiviral response in the host. This IFN- γ response has also been sought and
422 observed in other vaccines against SARS-CoV-2, such as BNT162b1 designed by BioNTech ¹⁷
423 and a recombinant adenovirus type-5 vectored COVID-19 vaccine designed by CanSino ¹⁸.

424 In summary, immunization with CoronaVac is safe and induces robust humoral and
425 cellular responses, characterized by increased antibody titers against the S1-RBD with
426 neutralizing capacities, and the production of T cells that are specific for several SARS-CoV-2
427 antigens and were characterized by the secretion of Th1 cytokines.

428 **Acknowledgments**

429 This study was supported by the Ministry of Health, Government of Chile; The
430 Confederation of Production and Commerce, Chile; the Consortium of Universities for Vaccines
431 and Therapies against COVID-19, Chile; the Chilean Public Health Institute (ISP); and the
432 Millennium Institute on Immunology and Immunotherapy. NIH contracts 75N93019C00001(A.S)
433 and 75N9301900065 supported A.S, D.W. We would like to thank the support of the Ministry of
434 Science, Technology, Knowledge, and Innovation, Government of Chile; and The Ministry of
435 Foreign Affairs, Government of Chile. We also would like to thank PATH for sharing the First
436 WHO International Standard for anti-SARS-CoV-2 immunoglobulin; Alex Cabrera and Sergio
437 Bustos from the Flow Cytometry Facility at Facultad de Ciencias Biológicas, Pontificia
438 Universidad Católica de Chile for support with flow cytometry; and Sebastián Silva from the
439 same Faculty for support with statistical analyses. We also thank the Vice Presidency of
440 Research (VRI), the Direction of Technology Transfer and Development (DTD), the Legal Affairs
441 Department (DAJ) and the Administrative Direction from the School of Biological Sciences and
442 the School of Medicine of the Pontificia Universidad Católica de Chile. Special thanks to the
443 members of the CoronaVac03CL Study Team (list in Supplementary Appendix) for their hard
444 work and dedication to the clinical study; the members of the independent data safety
445 monitoring committee (members in Supplementary Appendix) for their oversight, and the
446 subjects enrolled in the study for their participation and commitment to this trial.

447 **Declaration of interest**

448 A.S. is a consultant for Gritstone, Flow Pharma, Merck, Epitogenesis, Gilead and Avalia.
449 LJI has filed for patent protection for various aspects of T cell epitope and vaccine design work.
450 All other authors declare no conflict of interest.

451 **References**

- 452 1 Zhu N, Zhang D, Wang W, *et al.* A Novel Coronavirus from Patients with Pneumonia in
453 China, 2019. *N Engl J Med* 2020; **382**: 727–33.
- 454 2 Kim D, Lee J-Y, Yang J-S, Kim JW, Kim VN, Chang H. The Architecture of SARS-CoV-2
455 Transcriptome. *Cell* 2020; **181**: 914–921.e10.
- 456 3 Zhou P, Yang X-L, Wang X-G, *et al.* A pneumonia outbreak associated with a new
457 coronavirus of probable bat origin. *Nature* 2020; **579**: 270–3.
- 458 4 Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real
459 time. *Lancet Infect Dis* 2020; **20**: 533–4.
- 460 5 Perez-Saez J, Lauer SA, Kaiser L, *et al.* Serology-informed estimates of SARS-CoV-2
461 infection fatality risk in Geneva, Switzerland. *Lancet Infect Dis* 2020; published online July
462 14. DOI:10.1016/S1473-3099(20)30584-3.
- 463 6 O'Driscoll M, Ribeiro Dos Santos G, Wang L, *et al.* Age-specific mortality and immunity
464 patterns of SARS-CoV-2. *Nature* 2021; **590**: 140–5.
- 465 7 WHO Covid-19. Draft landscape of COVID-19 candidate vaccines. 2020
466 [https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-](https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines%0Ahttps://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines%0D)
467 [vaccines%0Ahttps://www.who.int/publications/m/item/draft-landscape-of-covid-19-](https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines%0Ahttps://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines%0D)
468 [candidate-vaccines%0D](https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines%0Ahttps://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines%0D).
- 469 8 Krammer F. SARS-CoV-2 vaccines in development. *Nature* 2020; **586**: 516–27.
- 470 9 Gao Q, Bao L, Mao H, *et al.* Development of an inactivated vaccine candidate for SARS-
471 CoV-2. *Science* 2020; **369**: 77–81.
- 472 10 Zhang Y, Zeng G, Pan H, *et al.* Safety, tolerability, and immunogenicity of an inactivated
473 SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind,
474 placebo-controlled, phase 1/2 clinical trial. *Lancet Infect Dis* 2021; **21**: 181–92.
- 475 11 Wu Z, Hu Y, Xu M, *et al.* Safety, tolerability, and immunogenicity of an inactivated SARS-
476 CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised,
477 double-blind, placebo-controlled, phase 1/2 clinical trial. *Lancet Infect Dis* 2021; published

- 478 online Feb 3. DOI:10.1016/S1473-3099(20)30987-7.
- 479 12 World Medical Association. World Medical Association Declaration of Helsinki: ethical
480 principles for medical research involving human subjects. *JAMA* 2013; **310**: 2191–4.
- 481 13 Grifoni A, Weiskopf D, Ramirez SI, *et al.* Targets of T Cell Responses to SARS-CoV-2
482 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. *Cell* 2020;
483 **181**: 1489–1501.e15.
- 484 14 WHO Working Group on the Clinical Characterisation and Management of COVID-19
485 infection. A minimal common outcome measure set for COVID-19 clinical research.
486 *Lancet Infect Dis* 2020; **20**: e192–7.
- 487 15 Beltrán-Pavez C, Riquelme-Barrios S, Oyarzún-Arrau A, *et al.* Insights into neutralizing
488 antibody responses in individuals exposed to SARS-CoV-2 in Chile. *Sci Adv* 2021; **7**:
489 eabe6855.
- 490 16 Kang I, Hong MS, Nolasco H, *et al.* Age-associated change in the frequency of memory
491 CD4+ T cells impairs long term CD4+ T cell responses to influenza vaccine. *J Immunol*
492 2004; **173**: 673–81.
- 493 17 Sahin U, Muik A, Derhovanessian E, *et al.* COVID-19 vaccine BNT162b1 elicits human
494 antibody and TH1 T cell responses. *Nature* 2020; **586**: 594–9.
- 495 18 Zhu F-C, Li Y-H, Guan X-H, *et al.* Safety, tolerability, and immunogenicity of a
496 recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-
497 label, non-randomised, first-in-human trial. *Lancet (London, England)* 2020; **395**: 1845–
498 54.
- 499

500 Tables and Figures

Table 1. Characteristics of the Participants at Baseline

Characteristic	18-59 years old (n = 397)	≥ 60 years old (n = 37)	Total (n = 434)	p-value
Age mean, SD	38.2 ± 9.7	64.0 ± 4.3	40.4 ± 11.8	
Inoculation				
Vaccine; n (%)	245 (61.7)	25 (67.6)	270 (62.2)	0.482
Placebo; n (%)	152 (38.3)	12 (32.4)	164 (37.8)	
Sex				
Women; n (%)	251 (63.2)	17 (45.9)	268 (61.8)	0.039
Men; n (%)	146 (36.8)	20 (54.1)	166 (38.2)	
Ethnicity				
White; n (%)	370 (93.2)	37 (100.0)	407 (93.8)	0.152
Other; n (%)	27 (6.8)	0 (0.0)	27 (6.2)	

P-values are for comparison between total numbers in each characteristic.

501

Table 2. Solicited Local and Systemic Adverse Events after inoculation in Participants, classified by arm and age group

Adverse Reaction	First dose (n =434)			Second dose (n =319)			Both Doses (n =319)		
	Placebo (n=164)	Vaccine (n=270)	p-value	Placebo (n=80)	Vaccine (n=239)	p-value	Placebo (n=80)	Vaccine (n=239)	p-value
Local reactions									
Pain; n (%)	39 (23.8)	117 (43.3)	<0.001	16 (20.0)	73 (30.5)	0.069	32 (40.0)	133 (55.6)	0.015
<60 years	37 (24.3)	113 (46.1)	<0.001	15 (20.8)	68 (31.8)	0.077	30 (41.7)	125 (58.4)	0.014
≥60 years	2 (16.7)	4 (16.0)	0.999	1 (12.5)	5 (20.0)	0.999	2 (25.0)	8 (32.0)	0.999
Induration (%)	1 (0.6)	8 (3.0)	0.163	0 (0.0)	15 (6.3)	0.015	0 (0.0)	21 (8.8)	0.006
<60 years	1 (0.7)	7 (2.9)	0.161	0 (0.0)	13 (6.1)	0.043	0 (0.0)	18 (8.4)	0.009
≥60 years	0 (0.0)	1 (4.0)	0.999	0 (0.0)	2 (8.0)	0.999	0 (0.0)	3 (12.0)	0.56
Pruritus (%)	4 (2.4)	15 (5.6)	0.124	2 (2.5)	6 (2.5)	0.099	3 (3.8)	17 (7.1)	0.283
<60 years	4 (2.6)	15 (6.1)	0.113	2 (2.8)	6 (2.8)	0.099	3 (4.2)	17 (7.9)	0.277
≥60 years	0 (0.0)	0 (0.0)	---	0 (0.0)	0 (0.0)	---	0 (0.0)	0 (0.0)	---
Erythema (%)	3 (1.8)	10 (3.7)	0.386	2 (2.5)	3 (1.3)	0.602	2 (2.5)	10 (4.2)	0.737
<60 years	3 (2.0)	10 (4.1)	0.385	1 (1.4)	3 (1.4)	0.999	1 (1.4)	10 (4.7)	0.301
≥60 years	0 (0.0)	0 (0.0)	---	1 (12.5)	0 (0.0)	0.242	1 (12.5)	0 (0.0)	0.242
Swelling (%)	3 (1.8)	5 (1.9)	0.999	1 (1.3)	5 (2.1)	0.999	1 (1.3)	9 (3.8)	0.461
<60 years	3 (2.0)	5 (2.0)	0.999	1 (1.4)	4 (1.9)	0.999	1 (1.4)	8 (3.7)	0.458
≥60 years	0 (0.0)	0 (0.0)	---	0 (0.0)	1 (4.0)	0.999	0 (0.0)	1 (4.0)	0.999
Systemic reactions									
Headache (%)	50 (30.5)	107 (39.6)	0.055	15 (18.8)	46 (19.2)	0.922	39 (48.8)	116 (48.5)	0.974
<60 years	49 (32.2)	102 (41.6)	0.061	12 (16.7)	42 (19.6)	0.579	36 (50.0)	109 (50.9)	0.891
≥60 years	1 (8.3)	5 (20.0)	0.641	3 (37.5)	4 (16.0)	0.32	3 (37.5)	7 (28.0)	0.673
Fatigue (%)	32 (19.5)	58 (21.5)	0.624	10 (12.5)	25 (10.5)	0.613	22 (27.5)	64 (26.8)	0.9
<60 years	31 (20.4)	55 (22.4)	0.629	8 (11.1)	23 (10.7)	0.932	20 (27.8)	60 (28.0)	0.966
≥60 years	1 (8.3)	3 (12.0)	0.999	2 (25.0)	2 (8.0)	0.241	2 (25.0)	4 (16.0)	0.616
Myalgia (%)	23 (14.0)	48 (17.8)	0.305	9 (11.3)	19 (7.9)	0.367	19 (23.8)	54 (22.6)	0.831
<60 years	22 (14.5)	46 (18.8)	0.269	8 (11.1)	16 (7.5)	0.336	18 (25.0)	50 (23.4)	0.778
≥60 years	1 (8.3)	2 (8.0)	0.999	1 (12.5)	3 (12.0)	0.999	1 (12.5)	4 (16.0)	0.999
Diarrhea (%)	18 (11.0)	36 (13.3)	0.471	5 (6.3)	18 (7.5)	0.701	15 (18.8)	44 (18.4)	0.946
<60 years	17 (11.2)	36 (14.7)	0.318	4 (5.6)	16 (7.5)	0.58	14 (19.4)	42 (19.6)	0.973

≥60 years	1 (8.3)	0 (0.0)	0.324	1 (12.5)	2 (8.0)	0.999	1 (12.5)	2 (8.0)	0.999
Nausea (%)	18 (11.0)	25 (9.3)	0.562	3 (3.8)	9 (3.8)	0.999	11 (13.8)	27 (11.3)	0.558
<60 years	18 (11.8)	22 (9.0)	0.357	2 (2.8)	9 (4.2)	0.736	10 (13.9)	24 (11.2)	0.544
≥60 years	0 (0.0)	3 (12.0)	0.537	1 (12.5)	0 (0.0)	0.242	1 (12.5)	3 (12.0)	0.999
Arthralgia (%)	10 (6.1)	14 (5.2)	0.687	2 (2.5)	7 (2.9)	0.999	7 (8.8)	18 (7.5)	0.726
<60 years	10 (6.6)	13 (5.3)	0.596	2 (2.8)	6 (2.8)	0.999	7 (9.7)	16 (7.5)	0.544
≥60 years	0 (0.0)	1 (4.0)	0.999	0 (0.0)	1 (4.0)	0.999	0 (0.0)	2 (8.0)	0.999
Anorexia (%)	10 (6.1)	18 (6.7)	0.815	3 (3.8)	3 (1.3)	0.169	6 (7.5)	16 (6.7)	0.806
<60 years	10 (6.6)	16 (6.5)	0.985	2 (2.8)	3 (1.4)	0.603	5 (6.9)	14 (6.5)	0.999
≥60 years	0 (0.0)	2 (8.0)	0.999	1 (12.5)	0 (0.0)	0.242	1 (12.5)	2 (8.0)	0.999
Pruritus (%)	2 (1.2)	10 (3.7)	0.225	0 (0.0)	4 (1.7)	0.575	1 (1.3)	14 (5.9)	0.127
<60 years	2 (1.3)	9 (3.7)	0.217	0 (0.0)	4 (1.9)	0.575	1 (1.4)	13 (6.1)	0.202
≥60 years	0 (0.0)	1 (4.0)	0.999	0 (0.0)	0 (0.0)	---	0 (0.0)	1 (4.0)	0.999
Exanthema (%)	1 (0.6)	7 (2.6)	0.268	0 (0.0)	1 (0.4)	0.999	1 (1.3)	8 (3.3)	0.459
<60 years	1 (0.7)	7 (2.9)	0.161	0 (0.0)	1 (0.5)	0.999	1 (1.4)	8 (3.7)	0.458
≥60 years	0 (0.0)	0 (0.0)	---	0 (0.0)	0 (0.0)	---	0 (0.0)	0 (0.0)	---
Allergy (%)	1 (0.6)	6 (2.2)	0.262	0 (0.0)	3 (1.3)	0.575	0 (0.0)	8 (3.3)	0.209
<60 years	0 (0.0)	5 (2.0)	0.161	0 (0.0)	2 (0.9)	0.999	0 (0.0)	4 (1.9)	0.575
≥60 years	1 (8.3)	1 (4.0)	0.999	0 (0.0)	1 (4.0)	0.999	0 (0.0)	1 (4.0)	0.999
Vomiting (%)	3 (1.8)	1 (0.4)	0.154	0 (0.0)	4 (1.7)	0.575	0 (0.0)	4 (1.7)	0.575
<60 years	3 (2.0)	1 (0.4)	0.159	0 (0.0)	4 (1.9)	0.575	0 (0.0)	4 (1.9)	0.575
≥60 years	0 (0.0)	0 (0.0)	---	0 (0.0)	0 (0.0)	---	0 (0.0)	0 (0.0)	---
Fever (>37.8°C) (%)	1 (0.6)	1 (0.4)	0.999	0 (0.0)	0 (0.0)	---	1 (1.3)	1 (0.4)	0.439
<60 years	1 (0.7)	1 (0.4)	0.999	0 (0.0)	0 (0.0)	---	1 (1.4)	1 (0.5)	0.441
≥60 years	0 (0.0)	0 (0.0)	---	0 (0.0)	0 (0.0)	---	0 (0.0)	0 (0.0)	---

Percentages were calculated from the total number of participants in each group.

Data in the table were reported within 7 days post any of the two doses.

Sample sizes: Placebo <60 1st dose: n=152; Placebo <60 2nd dose: n=72; Vaccine <60 1st dose: n=245; Vaccine <60 2nd dose: n=214; Placebo ≥ 60 1st dose: n=12 ; Placebo ≥60 2nd dose: n=8 ; Vaccine ≥60 1st dose: n=25; Vaccine ≥60 years 2nd dose: n=25.

Table 3. Seroconversion rates and Geometric median titer of antibodies against SARS-CoV-2 proteins

Antibodies detected	Group	Indicators	Day 14	Day 28	Day 42
Anti-S1-RBD IgG	Total Vaccine	Seroconversion n/N	13/34	32/33	29/31
		(%)	(38.2)	(96.9)	(93.5)
		GMT (95%CI)	21.9 (6.7-71.7)	2015.9 (1382-2940)	1686.6 (948-3001)
	18-59 years	Seroconversion n/N	11/23	22/23	22/23
		(%)	(47.8)	(95.6)	(95.6)
		GMT (95%CI)	45.1 (10-203.2)	1860.2 (1174-2948)	2036.2 (477-2807)
	≥ 60 years	Seroconversion n/N	2/11	10/10	7/8
		(%)	(18.1)	(100)	(87.5)
		GMT (95%CI)	4.81 (0.7-31.6)	2425.2 (1109-5302)	981.2 (87-11064)
	Placebo	Seroconversion n/N	1/12	1/10	0/0
		(%)	(8.3)	(10)	N/D
		GMT (95%CI)	2.4 (0.6-9.1)	3.1 (0.6-9.4)	N/D N/D
Anti-N IgG	Total Vaccine	Seroconversion n/N	2/34	6/33	6/31
		(%)	(5.9)	(18.2)	(19.4)
		GMT (95%CI)	5.4 (2.1-13.7)	8.5 (2.98-24)	12.8 (4.4-37.7)
	18-59 years	Seroconversion n/N	2/23	4/23	3/23
		(%)	(8.7)	(17.4)	(13.0)
		GMT (95%CI)	5.3 (1.7-17)	8.0 (2.2-29.2)	9.2 (2.6-32.7)
	≥ 60 years	Seroconversion n/N	0/11	2/10	3/8
		(%)	(0)	(20.0)	(37.5)
		GMT (95%CI)	5.5 (0.7-38.6)	9.6 (1.1-81.5)	32.6 (2.7-398.4)
	Placebo	Seroconversion n/N	1/12	0/10	0/0
		(%)	(8.3)	(0)	(-)
		GMT (95%CI)	5.8 (1-33.34)	3.1 (0.5-17.6)	N/D (-)
Neutralizing anti-S1-RBD	Total Vaccine	Seroconversion n/N	N/D	31/33	32/33
		(%)	(-)	(94)	(97)
		GMT (95%CI)	N/D (-)	16.3 (10.3-25.9)	23.85 (14.3-39.7)
	18-59 years	Seroconversion n/N	N/D	22/23	22/23
		(%)	(-)	(95.7)	(95.7)

	GMT (95%CI)	N/D (-)	15.1 (8.8-25.7)	17.5 (9.2-33.2)
≥ 60 years	Seroconversion n/N (%)	N/D (-)	9/10 (90.0)	10/10 (100)
	GMT (95%CI)	N/D (-)	39.4 (9.5-163.4)	48.5 (22.2-106)
Placebo	Seroconversion n/N (%)	N/D (-)	0/11 (0)	N/D (-)
	GMT (95%CI)	N/D (-)	0 (0)	N/D (-)

Timepoints refer to the number of days after the first dose of vaccine or placebo in the schedule; RBD: Receptor-binding domain; S: Spike; N: Nucleoprotein; GMT: Geometric mean titer; N/D: No determined.




Figure 1. Study profile. Recruitment of volunteers as of January 08th, 2021.




Figure 2: Immunization with CoronaVac induces specific IgG against SARS-CoV-2 antigens in participants aged 18-59 and ≥ 60 after two immunizations in a 0-14 schedule.

Titers of IgG antibodies after two doses of CoronaVac were evaluated for immunized participants (excluding seropositive participants at recruitment and placebo participants) at 0, 14, 28, and 42 days post the first immunization (p.i.) for adults aged 18-59 (**A**, **C**), and ≥ 60 (**B**, **D**) for specific IgG against the S1-RBD (upper panel) and the N protein (lower panel) of SARS-CoV-2. Data are expressed as the reciprocal antibody titer v/s time after the first dose. Error bars indicate the 95% CI of the Geometric Mean Titer (GMT). The spots represent the individual values of antibody titers, with the numbers above the spots showing the GMT estimates. The graph illustrates the results obtained for 23 participants in the 18-59 years old group and 11 participants in the ≥ 60 years old group. A Wilcoxon test was performed to compare the samples

of day 0 against the rest of the groups; * $p < 0.05$, ** $p < 0.005$, *** $p < 0.0005$, **** $p < 0.0001$.




Figure 3. Immunization with CoronaVac induces neutralizing antibodies against SARS-CoV-2 in participants aged 18-59 and ≥ 60 after two immunizations in a 0-14 schedule. Neutralizing antibody titers were evaluated with a surrogate virus neutralization assay, which quantifies the interaction between S1-RBD and hACE2 pre-coated on ELISA plates. Results were obtained from participants aged (A) 18-59 and (B) ≥ 60 at 0, 28, and 42 days p.i. Data is represented as the reciprocal antibody titer v/s time after the first dose. Numbers above the bars show the Geometric Mean Titer (GMT), and the error bars indicate the 95% CI. Data were analyzed by a Wilcoxon test to compare against day 0; * $p < 0.05$, ** $p < 0.005$, *** $p < 0.0005$, **** $p < 0.0001$. (C) Percentage of inhibition of the neutralizing antibodies at 1:4, 1:8, and 1:16 dilutions of sera from vaccinated participants. The graph represents the results obtained for 23 participants in the 18-59 years old group and 10 participants in the ≥ 60 years old group. Dotted lines indicate the cut-off value, set at 30%. Data were analyzed by a two-tailed Student's t-test against day 0; **** $p < 0.0001$




Figure 4. Quantification of IFN- γ -secreting CD4⁺ T cells, upon stimulation with two Mega Pools of peptides derived from SARS-CoV-2 proteins (MP-S and MP-R) in participants aged 18-59 and ≥ 60 immunized with CoronaVac. Absolute count of IFN- γ -secreting cells, determined by ELISPOT as Spot Forming Cells (SFCs), was measured upon stimulation of PBMC with MP-S (A) and MP-R (B), for 48 h in samples obtained at 0, 28, and 42 days p.i. The absolute number of activated CD4⁺ T cells (defined as CD3⁺, CD69⁺) secreting IFN- γ , as determined by flow cytometry, was measured upon stimulation for 24 h with MP-S (C) and MP-R (D) in samples obtained at 0, 28, and 42 days p.i. A total of 25 samples stimulated with MP-S and 27 samples stimulated with MP-R were considered in the 18-59 years old group and 9 samples for the ≥ 60 years old group. Data shown represent means \pm SD. Data from each age group were analyzed separately by a Friedman test for repeated measures, followed by a *post hoc* Dunn's test corrected for multiple comparisons against day 0 for each age group; *= $p < 0.05$, **= $p < 0.005$.




Figure 5. Quantification of IFN- γ -secreting CD8⁺ T cells, upon stimulation with two Mega Pools of peptides derived from SARS-CoV-2 proteins (MP-CD8A and CD8B) in participants aged 18-59 and ≥ 60 , immunized with CoronaVac. Absolute count of IFN- γ -secreting cells, determined by ELISPOT as Spot Forming Cells (SFCs), was measured upon stimulation of PBMC with MP-CD8A (A) and MP-CD8B (B) for 48 h in samples obtained at 0, 28, and 42 days p.i.. The absolute number of activated CD8⁺ T cells (defined as CD3⁺, CD69⁺) secreting IFN- γ , determined by flow cytometry, was measured upon stimulation for 24 h with MP-CD8A (C) and MP-CD8B (D) in samples obtained at 0, 28, and 42 days p.i.. A total of 7 participants were considered in the 18-59 years old group and 7 participants for the ≥ 60 years old group. Data shown represent mean \pm SD. Data from each age group were analyzed separately by a Friedman test for repeated measures, followed by a *post hoc* Dunn's test corrected for multiple comparisons against day 0 for each age group.